ZA90982B - Cross-linked antibodies - Google Patents

Cross-linked antibodies

Info

Publication number
ZA90982B
ZA90982B ZA90982A ZA90982A ZA90982B ZA 90982 B ZA90982 B ZA 90982B ZA 90982 A ZA90982 A ZA 90982A ZA 90982 A ZA90982 A ZA 90982A ZA 90982 B ZA90982 B ZA 90982B
Authority
ZA
South Africa
Prior art keywords
cross
antibody
tumour
conjugates
bridge
Prior art date
Application number
ZA90982A
Other languages
English (en)
Inventor
Stephen Keith Rhind
Keith Rhind Stephen
Original Assignee
Celltech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech Ltd filed Critical Celltech Ltd
Publication of ZA90982B publication Critical patent/ZA90982B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA90982A 1989-02-10 1990-02-09 Cross-linked antibodies ZA90982B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898903021A GB8903021D0 (en) 1989-02-10 1989-02-10 Chemical compounds

Publications (1)

Publication Number Publication Date
ZA90982B true ZA90982B (en) 1991-10-30

Family

ID=10651471

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA90982A ZA90982B (en) 1989-02-10 1990-02-09 Cross-linked antibodies

Country Status (15)

Country Link
EP (1) EP0385601B1 (de)
JP (1) JP2975677B2 (de)
KR (1) KR910700076A (de)
AT (1) ATE123653T1 (de)
AU (1) AU636872B2 (de)
CA (1) CA2026313A1 (de)
DE (1) DE69020007T2 (de)
GB (2) GB8903021D0 (de)
HU (1) HUT56289A (de)
IE (1) IE67448B1 (de)
IL (1) IL93346A0 (de)
NO (1) NO904368L (de)
NZ (1) NZ232489A (de)
WO (1) WO1990009196A1 (de)
ZA (1) ZA90982B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010176A (en) * 1988-11-10 1991-04-23 Eli Lilly And Company Antibody-drug conjugates
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
US5922618A (en) * 1996-03-04 1999-07-13 Matsushita Electric Industrial Co., Ltd. Dye-labeled antibody conjugate and preparation method thereof
US5990286A (en) * 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
DE19911329A1 (de) * 1998-03-27 2000-09-21 Benes Ivan Friedrich Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP2788020A4 (de) 2011-12-05 2015-04-29 Immunomedics Inc Therapeutische verwendung von anti-cd22-antikörpern zur induktion von trogozytose
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
WO2017139623A1 (en) 2016-02-10 2017-08-17 Immunomedics, Inc. Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
WO2018187074A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
CN111876460A (zh) * 2020-08-17 2020-11-03 郑州伊美诺生物技术有限公司 鼠单抗IgG2a F(ab`)2的制备方法
CN117466980A (zh) * 2023-11-02 2024-01-30 浙江普罗亭健康科技有限公司 基于多肽链骨架应用于金属抗体标记的负载金属缀合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751286A (en) * 1985-11-19 1988-06-14 The Johns Hopkins University Protein label and drug delivery system
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product

Also Published As

Publication number Publication date
HU901927D0 (en) 1991-03-28
DE69020007D1 (de) 1995-07-20
EP0385601B1 (de) 1995-06-14
GB2236529B (en) 1993-03-31
IE67448B1 (en) 1996-04-03
CA2026313A1 (en) 1990-08-11
IL93346A0 (en) 1990-11-29
AU5081090A (en) 1990-09-05
EP0385601A2 (de) 1990-09-05
KR910700076A (ko) 1991-03-13
GB9021895D0 (en) 1990-11-21
NO904368L (no) 1990-12-10
HUT56289A (en) 1991-08-28
IE900493L (en) 1990-08-10
JP2975677B2 (ja) 1999-11-10
NO904368D0 (no) 1990-10-09
ATE123653T1 (de) 1995-06-15
AU636872B2 (en) 1993-05-13
DE69020007T2 (de) 1995-11-23
EP0385601A3 (de) 1990-11-14
JPH03504645A (ja) 1991-10-09
GB2236529A (en) 1991-04-10
NZ232489A (en) 1992-09-25
GB8903021D0 (en) 1989-03-30
WO1990009196A1 (en) 1990-08-23

Similar Documents

Publication Publication Date Title
ZA90982B (en) Cross-linked antibodies
ZA90983B (en) Cross-linked antibodies
GB9824632D0 (en) Biological compounds
NZ217829A (en) Monoclonal anti-human breast cancer antibodies and test reagent
NZ331978A (en) Monoclonal antibody to CEA (carcinomembryonic antigen), conjugates comprising said antibody, and their therapeutic use in an adept system
GR3025644T3 (en) Improved monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
ATE255633T1 (de) Humane b-lymphoblastoiden zellinie welche anti- gangliosid-antikörper sekretiert
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
GB8925590D0 (en) Monoclonal antibodies
DK402485A (da) Tumorterapeutiskum og fremgangsmaade til dets fremstilling
Rhind Crosslinked antibodies and processes for their preparation
FI954230A (fi) Diagnostiikassa käytettävä monoklonaalinen vasta-ainekoostumus ja sitä sisältävä testipakkaus
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.
EP0259773A3 (de) Ein Antikörper spezifisch gegen ein Krebsantigen